Leucosceptoside A

Leucosceptoside A at a Glance

Leucosceptoside A is a phenylethanoid glycoside (PhG) — the same structural family as verbascoside (acteoside), echinacoside and isoverbascoside. Structurally it is essentially verbascoside with one extra methyl group: the caffeoyl ester that defines verbascoside is replaced by a feruloyl ester, making leucosceptoside A the 3-O-methyl (feruloyl) analogue of acteoside ^{1,3Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 3Miyase T et al. · 1982Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et MurataView study →}.

It was first isolated in 1982 from the Japanese mint-family shrub Leucosceptrum japonicum, which gave it its name ^{3Reference 3Miyase T et al. · 1982Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et MurataView study →}. Since then it has turned up as a minor PhG across roughly eleven plant families — including several here, where it accompanies verbascoside rather than replacing it ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}.

Its evidence base is thin and mixture-heavy. Most reports are in-vitro assays of whole extracts in which leucosceptoside A is one phenolic among many; the isolated molecule has been tested cleanly in only a handful of studies. Treat this as a parked stub — the honest state of the literature is antioxidant and anti-inflammatory activity at the extract level, one isolated-molecule anti-inflammatory study, and preliminary neuroprotective/anticancer signals, with no human data ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}.

Leucosceptoside A vs. Verbascoside

The distinction between this molecule and its far better-studied relative is one methyl group, and it is the point of the page.

Verbascoside (acteoside) carries a caffeoyl ester — caffeic acid, with a free catechol (two adjacent phenolic hydroxyls) ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}. That catechol is the engine of verbascoside’s potent radical-scavenging and metal-chelating chemistry.

Leucosceptoside A carries a feruloyl ester instead: the caffeoyl 3-hydroxyl is methylated to a 3-methoxy group, converting caffeic acid into ferulic acid ^{1,3Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 3Miyase T et al. · 1982Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et MurataView study →}. Capping one of the two catechol hydroxyls removes a hydrogen-bond-donating -OH, which is the simplest explanation for why leucosceptoside A is a weaker antioxidant than verbascoside in head-to-head assays — its superoxide-scavenging SC₅₀ (~0.294 mM) is roughly four to five times higher (i.e. weaker) than verbascoside’s (~0.063 mM) ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}.

The same one-methyl logic separates it from its sibling martynoside, which adds a second methyl (on the phenylethanoid ring), and from isoverbascoside, a positional (4′→6′ acyl-migration) isomer of verbascoside. All belong to the caffeoyl/caffeic-acid-derived PhG series that this database also covers through rosmarinic acid and echinacoside.

What It's Used For

Leucosceptoside A’s pharmacology is preliminary and largely in-vitro. It is best read through its dedicated 2022 review ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}, which pooled the scattered activity data, plus a small number of primary studies.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here rests on in-vitro or cell data; there is no human evidence, so scores are low by construction.

01Anti-inflammatoryShaky32%Isolated molecule; PI3K/AKT in HaCaT keratinocytes + NO inhibition in macrophages ^{1,2Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 2Koycheva IK et al. · 2021Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in KeratinocytesView study →}

02AntioxidantShaky24%In-vitro radical scavenging; weaker than verbascoside; usually an extract constituent ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}

03Neuroprotective / AnticancerShaky16%Review-level; modest MPP⁺ protection + modest cytotoxicity, cell only ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}

Mechanisms

The one methyl group that turns caffeoyl into feruloyl is the load-bearing structural fact: it plausibly explains the weaker antioxidant potency relative to verbascoside, while the anti-inflammatory PI3K/AKT signal is the molecule’s most specific finding.

Pharmacokinetics

No pharmacokinetic data are characterised for leucosceptoside A. By close analogy to verbascoside — whose absolute oral bioavailability is only ~0.12% in rats because gut bacteria hydrolyse the glycoside before absorption — an intact PhG of this size and polarity would be expected to have poor oral bioavailability, which undercuts any in-vitro potency as a predictor of oral effect. This is an inference from the class, not a measured value for this molecule.

Clinical Trials

There are no clinical trials of leucosceptoside A, and no human data of any kind. All evidence is in-vitro or cell-based, most of it inside whole-extract screens.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits firmly on the whole-plant side of the divide. Its one clean isolated-molecule result is the psoriasis-keratinocyte study, where leucosceptoside A was purified from devil’s claw and tested on its own ^{2Reference 2Koycheva IK et al. · 2021Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in KeratinocytesView study →}. Almost everything else — the antioxidant, anti-glycation and neuroprotective readouts — comes from extract screens (blue vervain, mullein, devil’s claw, Cistanche and other PhG-rich plants) in which leucosceptoside A is a minor phenolic overshadowed by verbascoside ^{1,4Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 4Yokosuka A et al. · 2021Chemical Constituents of the Whole Plant of Verbena hastata and Their Inhibitory Activity Against the Production of AGEsView study →}. Because verbascoside is both more abundant and more potent, isolating leucosceptoside A’s own contribution from a PhG mixture is rarely attempted, and the transferability of any extract finding to the pure molecule is unproven.

Prevalence in Nature

Leucosceptoside A is taxonomically widespread but chemically minor. The dedicated review documents it across about eleven plant families — Acanthaceae, Asteraceae, Bignoniaceae, Lamiaceae (by far the richest, with the genera Phlomis, Stachys, Clerodendrum and Scutellaria), Linderniaceae, Malvaceae, Oleaceae, Orobanchaceae, Plantaginaceae, Scrophulariaceae and Verbenaceae ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}. In this database it appears in devil’s claw, blue vervain, mullein and wood betony, and beyond it in Cistanche, Paulownia and Markhamia species ^{1,2,4Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 2Koycheva IK et al. · 2021Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in KeratinocytesView study →Reference 4Yokosuka A et al. · 2021Chemical Constituents of the Whole Plant of Verbena hastata and Their Inhibitory Activity Against the Production of AGEsView study →}.

Two caveats define its occurrence. First, it is almost never quantified as the isolate — it is reported qualitatively, as one PhG among several, so no reliable concentration figures exist and no “Content by Source” chart can be built yet. Second, the review concludes it cannot serve as a chemotaxonomic marker at any level, precisely because it is so unspecifically distributed ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →}.

Discovery & Synthesis

Leucosceptoside A was first isolated in 1982 by Miyase and co-workers from the aerial parts of Leucosceptrum japonicum (Lamiaceae), reported together with acteoside (verbascoside) and martynoside; the compound is named for the source genus, Leucosceptrum ^{3Reference 3Miyase T et al. · 1982Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et MurataView study →}. As with other phenylethanoid glycosides, there is no established total synthesis of practical relevance — the molecule is obtained by extraction and chromatographic purification from PhG-rich plants (devil’s claw, Cistanche, mullein and related species), and any material used in research is plant-derived rather than manufactured ^{1,3Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →Reference 3Miyase T et al. · 1982Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et MurataView study →}.

Patents: not yet researched.

Toxicity & Safety

Leucosceptoside A carries a low toxicity flag — consistent with the phenylethanoid glycoside class generally and with its poorly absorbed, plant-food-derived nature. No specific toxicity, genotoxicity, reproductive or interaction data exist for the isolated molecule; the flag reflects the benign class profile and the absence of any reported adverse signal, not a dedicated safety dataset.

Safety at a Glance

✅ Low / no toxicity

• Benign phenylethanoid-glycoside class. No reported toxicity for the isolate; related PhGs (verbascoside, echinacoside) are well tolerated in animal work.
• No isolate safety dataset. No genotoxicity, repeat-dose, interaction or reproductive-toxicity studies exist for leucosceptoside A specifically — safety is inferred from the class, not demonstrated.
• Human exposure is dietary/herbal only. It reaches people as a minor constituent of PhG-rich botanicals (devil’s claw, mullein), not as an isolated supplement; intake decisions belong to the herb or product page.

Dosage

There is no established human dose for leucosceptoside A, and it is not sold or used as an isolated supplement. Reported figures are laboratory concentrations from in-vitro work — for example nitric-oxide inhibition at an IC₅₀ near 9 µM and radical-scavenging in the micromolar-to-millimolar range ^{1Reference 1Frezza C et al. · 2022Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological ActivitiesView study →} — not doses that have been taken by people. Human exposure is indirect, as a minor phenylethanoid glycoside within whole botanicals such as devil’s claw and mullein. These are research concentrations and are not a personal recommendation.

References

1. Frezza C, De Vita D, Toniolo C, et al. (2022). Leucosceptosides A and B: Two Phenyl-Ethanoid Glycosides with Important Occurrence and Biological Activities. Biomolecules. https://pubmed.ncbi.nlm.nih.gov/36551235/
2. Koycheva IK, Mihaylova LV, Todorova MN, Balcheva-Sivenova ZP, Alipieva K, Ferrante C, Orlando G, Georgiev MI (2021). Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes. Molecules. https://pubmed.ncbi.nlm.nih.gov/34834106/
3. Miyase T, Koizumi A, Ueno A, Noro T, Kuroyanagi M, Fukushima S, Akiyama Y, Takemoto T (1982). Studies on the acyl glycosides from Leucosceptrum japonicum (Miq.) Kitamura et Murata. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.30.2732
4. Yokosuka A, Honda M, Kondo H, Mimaki Y (2021). Chemical Constituents of the Whole Plant of Verbena hastata and Their Inhibitory Activity Against the Production of AGEs. Natural Product Communications. https://doi.org/10.1177/1934578X211009727